| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 06.11. | MHRA champions patient voices through new policy | ||
| 06.11. | Armada to combine with Brains Bioceutical in $750m deal | ||
| 06.11. | Alfasigma receives EC's expanded approval for filgotinib to treat axSpA | ||
| 05.11. | Cordavis to stay in CVS Health after bifurcation of $117bn empire | ||
| 05.11. | Big pharma-backed T-Therapeutics snags $133m to bring TCEs to clinic | ||
| 05.11. | Evommune signs $1.1bn licence deal with Hinova for EVO570 | ||
| 05.11. | PharmatrophiX and Circular partner on neurodegenerative drugs | ||
| 04.11. | Trump's healthcare plans under contention after Democrats' midterm landslide | ||
| 04.11. | Boehringer signs oncology deal with Sino Biopharm worth up to $7.4bn | ||
| 04.11. | AbbVie bolsters UK R&D presence, inks $1.38bn IBD deal with Nxera | ||
| 04.11. | GEBRO and Spektus sign collaboration for ActraFlex | ||
| 04.11. | FDA to review uniQure's BLA for Huntington's gene therapy | ||
| 03.11. | FDA calls for stronger potency upkeep in CGT manufacturing | ||
| 03.11. | AbbVie inks $757m migraine-focused deal with Brise Pharmaceuticals | ||
| 03.11. | Lonza to acquire five US manufacturing sites from Merck KGaA | ||
| 03.11. | Bavarian Nordic secures four-year UK vaccine supply deal | ||
| 02.11. | Fresenius and WuXi team up in 37-strong biosimilar development deal | ||
| 02.11. | Pelthos and Castle Creek plan merger to target skin diseases | ||
| 02.11. | Inovio's Voceryq receives FDA accelerated approval for RRP | ||
| 30.10. | Casgevy gains UK label expansion for younger patient population | ||
| 30.10. | Eli Lilly's tirzepatide outperforms big pharma companies in Q3 | ||
| 30.10. | Glenmark opens Allentown distribution hub in US | ||
| 30.10. | Dren Bio raises $350m for dibotatug clinical development | ||
| 29.10. | RFK Jr backs compounding of six unapproved peptides in new policy | ||
| 29.10. | UK Budget light on life sciences but more doors open for biotech startups |